MedElevator Войти в исследования
← Поиск публикаций

DOI 10.64898/2026.04.06.716693

Медицинская библиотека · bioRxiv : the preprint server for biology · 2026

A VLP-based immunogen that elicits selective anti-Myostatin antibodies, enhances muscle mass and strength, and reduces adiposity.

Jacquez Quiteria, Peabody Julianne, Acosta Eduardo Hernandez, Chackerian Bryce, Endicott S Joseph

СтатьяПрепринтПеревод пока не подготовлен

Аннотация

Myostatin (MSTN) is a TGFβ family ligand that restricts muscle growth. Genetic loss-of-function in MSTN increases muscle mass, reduces fat accumulation, and improves metabolic health in mice and humans, with no known adverse phenotypes. Thus, depleting MSTN has therapeutic potential for obesity, sarcopenia, and other muscle wasting conditions. Recently developed monoclonal antibodies (mAbs) targeting MSTN or its receptors are expensive, require frequent injections/infusions, and risk a loss of efficacy from the development of anti-drug antibodies. Here, we report a comparatively inexpensive and durable alternative to mAbs, a virus-like particle (VLP)-based active immunotherapy, termed "MS2.87-97", that elicits an antibody response against a discrete and unique epitope in mature MSTN protein, with no cross-reactivity to GDF11. Compared to controls, MS2.87-97-treated mice had less age-associated weight gain and exhibited significantly reduced body fat by DEXA scan. MS2.87-97-treated mice also had significantly improved bodyweight-adjusted grip strength, and upon dissection, they were found to have increased muscle mass. No major safety concerns were identified. Echocardiography revealed no evidence of functional impairment of the heart, and histological analysis showed no change in myocardial collagen deposition (fibrosis). These initial findings support the continued preclinical development of MS2.87-97 as an immunotherapeutic for treating obesity, sarcopenia, and muscle wasting.

Для цитирования: Jacquez Quiteria, Peabody Julianne, Acosta Eduardo Hernandez, Chackerian Bryce, Endicott S Joseph. A VLP-based immunogen that elicits selective anti-Myostatin antibodies, enhances muscle mass and strength, and reduces adiposity.. bioRxiv : the preprint server for biology. 2026. DOI: 10.64898/2026.04.06.716693.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.